antipyrine has been researched along with Breast Neoplasms in 10 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The influence of two progestins, medroxyprogesterone acetate (MPA) and megestrol acetate (MA), given orally in high doses, on the pharmacokinetics of antipyrine, digitoxin, and warfarin were studied in patients with advanced breast cancer." | 7.67 | Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer. ( Bakke, O; Kvinnsland, S; Lundgren, S; Ueland, PM; Utaaker, E, 1986) |
| "Antipyrine was given as a single test dose before and after 3 mo of AG treatment, whereas theophylline and digitoxin kinetics were investigated at steady state in patients receiving these drugs therapeutically before and after AG therapy." | 5.27 | Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. ( Bakke, OM; Kvinnsland, S; Lønning, E, 1984) |
| "Aminoglutethimide is an aromatase inhibitor that is successfully used for endocrine treatment of advanced breast cancer." | 3.68 | Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. ( Lønning, PE, 1990) |
| "The influence of two progestins, medroxyprogesterone acetate (MPA) and megestrol acetate (MA), given orally in high doses, on the pharmacokinetics of antipyrine, digitoxin, and warfarin were studied in patients with advanced breast cancer." | 3.67 | Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer. ( Bakke, O; Kvinnsland, S; Lundgren, S; Ueland, PM; Utaaker, E, 1986) |
| " We have compared the cytotoxicity in human MCF-7 breast cancer cells of 125IUdR, 125I-iodotamoxifen, a nonsteroidal antiestrogen that is translocated from the cytoplasm to the nucleus of receptor containing cells, and 125I-iodoantipyrine, a biological indicator of the body water space." | 3.66 | Estrogen receptor-mediated cytotoxicity using iodine-125. ( Adelstein, SJ; Bloomer, WD; McLaughlin, WH; Milius, RA; Weichselbaum, RR, 1983) |
| "We tested in human breast cancer adenocarcinoma cell line MCF-7 whether ethanol affects ABCG2/BCRP, which is also the major transporter in human placenta." | 1.37 | Acute effects of ethanol on the transfer of nicotine and two dietary carcinogens in human placental perfusion. ( Auriola, S; Halonen, T; Karttunen, V; Myllynen, P; Myöhänen, K; Vähäkangas, K; Veid, J, 2011) |
| "Antipyrine was given as a single test dose before and after 3 mo of AG treatment, whereas theophylline and digitoxin kinetics were investigated at steady state in patients receiving these drugs therapeutically before and after AG therapy." | 1.27 | Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. ( Bakke, OM; Kvinnsland, S; Lønning, E, 1984) |
| " The mean phenazone half-life time (t0." | 1.27 | Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ( Cieślińska, A; Orzechowska-Juzwenko, K; Roszkowska, E; Wiela, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marković, V | 1 |
| Erić, S | 1 |
| Juranić, ZD | 1 |
| Stanojković, T | 1 |
| Joksović, L | 1 |
| Ranković, B | 1 |
| Kosanić, M | 1 |
| Joksović, MD | 1 |
| Veid, J | 1 |
| Karttunen, V | 1 |
| Myöhänen, K | 1 |
| Myllynen, P | 1 |
| Auriola, S | 1 |
| Halonen, T | 1 |
| Vähäkangas, K | 1 |
| Lønning, E | 1 |
| Kvinnsland, S | 2 |
| Bakke, OM | 1 |
| Bloomer, WD | 1 |
| McLaughlin, WH | 1 |
| Milius, RA | 1 |
| Weichselbaum, RR | 1 |
| Adelstein, SJ | 1 |
| Orzechowska-Juzwenko, K | 2 |
| Wiela-Hojeńska, A | 1 |
| Milejski, P | 1 |
| Cieślińska, A | 2 |
| Hudziec, P | 1 |
| Adamska, M | 1 |
| Simpson-Herren, L | 1 |
| Noker, PE | 1 |
| Lønning, PE | 1 |
| Preiss, R | 1 |
| Matthias, M | 1 |
| Sohr, R | 1 |
| Brockmann, B | 1 |
| Hüller, H | 1 |
| Lundgren, S | 1 |
| Utaaker, E | 1 |
| Bakke, O | 1 |
| Ueland, PM | 1 |
| Wiela, A | 1 |
| Roszkowska, E | 1 |
1 trial available for antipyrine and Breast Neoplasms
| Article | Year |
|---|---|
[Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
Topics: Acetylation; Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine | 1997 |
9 other studies available for antipyrine and Breast Neoplasms
| Article | Year |
|---|---|
Synthesis, antitumor activity and QSAR studies of some 4-aminomethylidene derivatives of edaravone.
Topics: Antineoplastic Agents; Antipyrine; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitu | 2011 |
Acute effects of ethanol on the transfer of nicotine and two dietary carcinogens in human placental perfusion.
Topics: Adenocarcinoma; Antipyrine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cas | 2011 |
Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antipyrine; Breast Neoplasms; Chromatography, High Pressure Liquid; | 1984 |
Estrogen receptor-mediated cytotoxicity using iodine-125.
Topics: Antipyrine; Breast Neoplasms; Cell Line; Cell Survival; Humans; Idoxuridine; Iodine Radioisotopes; R | 1983 |
Diversity of penetration of anti-cancer agents into solid tumours.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Agents; Antipyrine; Biological Transport; | 1991 |
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.
Topics: Aminoglutethimide; Antipyrine; Aromatase Inhibitors; Breast Neoplasms; Digitoxin; Drug Interactions; | 1990 |
Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.
Topics: Adult; Antipyrine; Breast Neoplasms; Carcinoma, Hepatocellular; Doxorubicin; Female; Humans; Liver F | 1987 |
Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antipyrine; Breast Neoplasms; Digitoxin; Female; Huma | 1986 |
Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Biotransformation; Breast N | 1987 |